Home
Products

Recombinant Proteins
Bioactive Proteins Cytokines and Growth Factors Immune Checkpoint Proteins Enzyme Other Proteins

Antibodies
Primary antibodies Recombinant Monoclonal Antibodies Secondary antibodies Flow Cytometry (FACS) Antibodies Neutralizing Antibodies Isotype Controls Research Grade Biosimilars InVivo Plus InVivo Antibodies XtenNano®Nanobodies Bispecific Antibodies Antibodies against Small Molecules Tag Antibodies Anti-idiotype Antibodies

Assay Kits
ELISA Kits ADA Assay Kits PK Assay Kits Antibody Pairs
Research Area
Featured Products
Support
Information
- BioSpotlight
- Literature Highlights
About Us
Promotion Center

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy

Cancer Cell

Lin et al. assemble a longitudinal pan-cancer single-cell atlas that tracks how the tumor immune microenvironment remodels during checkpoint inhibitor therapy. They show that the direction of remodeling, rather than the pre-treatment state, predicts response and translate these dynamics into a baseline gene signature that forecasts outcome across cancer types.

Related products

Catalog No.	Product Name	Description	Target
HS870036	Research Grade Balstilimab (Anti-PD-1)	Balstilimab (HS870036) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.	CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1

Recombinant Proteins

Antibodies

Assay Kits

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy

Quick access

Contact Us